Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-161-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral: 3.6 mg a.i./ kg bw/day, LOAEL for male rats (liver necrosis). OECD Guideline GLP study in rats with Zonyl surrogate administered for 90-days. NOAEL for liver effects 21.4 mg a.i./kg BW/day for female rats, LOAEL for male rats 3.6 mg a.i./kg BW/day. Classification for specific target organ toxicity is proposed. Reliability = 2.
Dermal: 357 mg a. i. /kg bw/day, a NOAEL for liver enzyme elevation was determined based on the observance of necrosis in the oral study, OECD Guideline 410, GLP study in male rats with surrogate administered for 28-days. NOAEL for liver enzyme elevation observed at administered dose of 1000 mg aqueous dispersion /kg BW/day. Reliability = 2.
Inhalation: 1.2 mg/m³ (total solids), NOAEL. OECD 412, GLP 2-week study in male and female rats. Minimal inflammation and minimal to mild mineralization of the U-shaped cartilage in rats exposed to 5.2 mg/m³ (total solids). Reliability = 2.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- LOAEL
- 3.6 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEC
- 1.2 mg/m³
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 357 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Additional information
Studies conducted on Zonyl were used as a read across for The Notified Substance (TNS). Zonyl is representative of the composition of TNS. It is a comparable mixture of mono, bis, pyro/poly and trifluoroalkyl phosphates as ammonium salts but which varies in carbon chain length and percentage composition. The carbon chain length varies from 4-12+ i. e. the repeating unit F(CF2) m where m = 4,6,8,10,12+ though m=6 and m=8 dominate the composition on a per weight percentage. As such it is expected that certain properties can be read-across. In this case, the Zonyl surrogate (~35.5% solids, ~ 20% isopropanol, and ~40-45% water) was the test substance administered. A 90-day oral rat study was performed at doses of 10, 60, or 300 mg/kg/day. Based on hepatocellular necrosis observed after a 90-day oral exposure in the 10 and 60 mg/kg/day groups as well as after one and three months of recovery in male rats of all dose levels, a NOEL was not determined for male rats. The NOEL for female rats was 60 mg/kg/day, based on elevated liver enzymes and thyroid gland hypertrophy observed in female rats administered 300 mg/kg/day. Since the Zonyl test material was ~35.5% solids, the adjusted NOEL is 36 mg a.i./kg bw/day for female rats and a NOEL was not determined for male rats. The LOEL was determined to be 3.6 mg a.i./kg bw/day for male rats based on mild hepatocellular necrosis observed among males treated with 3.6 or 36 mg a.i./kg bw/day at the end of the 90-day dosing period. The repeated dose toxicity potential of the TNS itself was assessed by administering 0, 5, 25, and 125 mg a.i. /kg bw/day via gavage to SD rats for 28 days. Main study animals (10 rats/sex/group) were sacrificed at the end of the dosing period.There were no test substance-related adverse effects on in-life parameters, clinical pathology, gross observations, organ weights, and microscopic findings. The increase in liver (males and females) and kidney (males) weights at 125 mg/kg/day as compared to controls noted at the end of exposure period was not considered adverse as there were no correlative microscopic findings. There were no organ weight changes following the recovery period. The NOAEL was 125 mg/kg/day. This study only provides supporting evidence that the effects of TNS are mild due to the congruent target organ effect on the liver. 28-days was not a sufficient dosing period to achieve the mild liver necrosis observed in the 90-day study with the analog material.
The NOAEC for repeated inhalation exposure (two-week inhalation study in rats) was 1.2 mg/m3, respirable particulate, based on histopathological findings in the respiratory tract. In a 28-day dermal study in rats, the NOEL was 100 mg/kg/day, based on the presence of mildly increased liver enzymes at 1000 mg/kg/day. Since the Zonyl material was 35.5% solids the adjusted LOEL is 357 mg a.i./kg bw/day and the NOEL is 35.7 mg a.i./kg bw/day.
An additional study was performed on a metabolite of TNS (sodium perfluoroheptanoate). In a GLP compliant 90-day study with reproductive and developmental toxicity screening, mice were exposed to the test substance via gavage at doses of 0, 0.5, 10, or 50 mg/kg/day. Adverse effects in the liver (hepatocellular hypertrophy with hepatocellular necrosis) were observed starting from the lowest dose level of 0.5 mg/kg bw/day. Associated changes in clinical chemistry included higher ALP, ALAT, and triglyceride values in high-dose males and higher ALP and triglyceride values in high-dose non-mated females, and higher relative liver weights at 10 and 50 mg/kg bw/day in both sexes. These changes were considered to be adverse. Therefore, the lowest dose level of 0.5 mg/kg bw/day was considered to be the LOAEL for systemic toxicity in the parental generation.
Repeated dose toxicity: via oral route - systemic effects
(target organ) digestive: liver
Repeated dose toxicity: inhalation - systemic effects (target organ)
respiratory: larynx
Repeated dose toxicity: dermal - systemic effects (target organ)
digestive: liver
Justification for classification or non-classification
After a 90-day oral exposure and/or after one and three months of recovery, mild hepatocellular necrosis was observed in male rats at all dose levels (10, 60, or 300 mg/kg bw/day). A NOEL was not determined for male rats. The NOEL for female rats was 60 mg/kg/day, based on elevated liver enzymes and thyroid gland hypertrophy observed in female rats administered 300 mg/kg/day. Since the Zonyl test material was ~35.5% solids, the adjusted NOEL is 36 mg a. i. /kg bw/day for female rats and a NOEL was not determined for male rats. The LOEL was determined to be 3.6 mg a. i. /kg bw/day for male rats based on mild hepatocellular necrosis observed among males treated with 3.6 or 36 mg a. i. /kg bw/day at the end of the 90-day dosing period. The histopathological observations were graded as minimal or mild and were not correlated with overt toxicity. Consistent with the CLP guidance minimal necrosis at all dose levels without the observation of any multifocal or moderate necrosis would be considered as a very mild effect using a weight of evidence approach. This conclusion is further supported by the results of the 28-day study on the TNS which resulted in only mild liver and kidney weight increases after 28-days of dosing up to 125 mg a. i. /kg bw/day. Therefore, the following classification applies, Category 2 repeated-dose specific target organ toxicity (STOT repeated) classification has been assigned for effects on the liver with repeated oral administration according to EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.